🇺🇸 FDA
Pipeline program

Belzutifan

6482-013

Phase 2 small_molecule active

Quick answer

Belzutifan for Carcinoma, Renal Cell is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Carcinoma, Renal Cell
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials